Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations

Journal of Translational Medicine

Volumn 9, Issue , 2011, Pages

  Niehr, Franziska ^a   von Euw, Erika ^a   Attar, Narsis ^a   Guo, Deliang ^a   Matsunaga, Doug ^a   Sazegar, Hooman ^a   Ng, Charles ^a   Glaspy, John A ^a,b   Recio, Juan A ^a   Lo, Roger S ^a,b   Mischel, Paul S ^a,b   Comin Anduix, Begonya ^a,c   Ribas, Antoni ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; METFORMIN; RO 5185426; UNCLASSIFIED DRUG; VEMURAFENIB; BRAF PROTEIN, HUMAN; GLUCOSE; INDOLE DERIVATIVE; PHOSPHOTHREONINE; PROTEIN KINASE B; SULFONAMIDE;

ARTICLE; BRAF GENE; CANCER INHIBITION; CELL GROWTH; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; GENE MUTATION; HUMAN; HUMAN CELL; MELANOMA CELL; MUTANT; ONCOGENE N RAS; TUMOR CELL LINE; WILD TYPE; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CULTURE MEDIUM; DRUG EFFECT; FLOW CYTOMETRY; GENETICS; MELANOMA; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TIME; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CULTURE MEDIA; DNA MUTATIONAL ANALYSIS; DRUG SYNERGISM; FLOW CYTOMETRY; GLUCOSE; HUMANS; INDOLES; MELANOMA; METFORMIN; MUTATION; PHOSPHORYLATION; PHOSPHOTHREONINE; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SULFONAMIDES; TIME FACTORS;

EID: 79956260998     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-76     Document Type: Article

References (21)

1. Padua RA, Barrass N, Currie GA. A novel transforming gene in a human malignant melanoma cell line. Nature 1984, 311:671-673. 10.1038/311671a0, 6090953.
2. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954. 10.1038/nature00766, 12068308.
3. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007, 445:851-857. 10.1038/nature05661, 17314971.
4. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819. 10.1056/NEJMoa1002011, 20818844.
5. Kefford R, Arkenau H, Brown MP, Millward M, Infante JR, Long GV, Ouellet D, Curtis M, Lebowitz PF, Falchokk GS. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. Proc American Society of Clinical Oncology 2010, 28:611s.
6. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973-977. 10.1038/nature09626, 21107323.
7. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 16;468(7326):968-72.
8. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010, 18:683-695. 10.1016/j.ccr.2010.11.023, 21156289.
9. Esteve-Puig R, Canals F, Colome N, Merlino G, Recio JA. Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF. PLoS One 2009, 4:e4771. 10.1371/journal.pone.0004771, 2651576, 19274086.
10. Zheng B, Jeong JH, Asara JM, Yuan YY, Granter SR, Chin L, Cantley LC. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell 2009, 33:237-247. 10.1016/j.molcel.2008.12.026, 2715556, 19187764.
11. Fogarty S, Hardie DG. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta 2010, 1804:581-591.
12. Corton JM, Gillespie JG, Hawley SA, Hardie DG. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells?. Eur J Biochem 1995, 229:558-565. 10.1111/j.1432-1033.1995.tb20498.x, 7744080.
13. Merrill GF, Kurth EJ, Hardie DG, Winder WW. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am J Physiol 1997, 273:E1107-1112.
14. Woodard J, Platanias LC. AMP-activated kinase (AMPK)-generated signals in malignant melanoma cell growth and survival. Biochemical and biophysical research communications 2010, 398:135-139. 10.1016/j.bbrc.2010.06.052, 20599746.
15. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, Cantley LC. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005, 310:1642-1646. 10.1126/science.1120781, 3074427, 16308421.
16. Sondergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S, Sazegar H, Macconaill LE, Barretina JG, Kehoe SM, et al. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific raf inhibitor PLX4032. J Transl Med 2010, 8:39. 10.1186/1479-5876-8-39, 2876068, 20406486.
17. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y, Bost F. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008, 27:3576-3586. 10.1038/sj.onc.1211024, 18212742.
18. Comin-Anduix B, Sazegar H, Chodon T, Matsunaga D, Jalil J, von Euw E, Escuin-Ordinas H, Balderas R, Chmielowski B, Gomez-Navarro J, et al. Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma. PLoS One 2010, 5:e12711. 10.1371/journal.pone.0012711, 2939876, 20856802.
19. Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, Czernin J, Shyy JY, Watson AD, Phelps M, et al. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci USA 2009, 106:12932-12937. 10.1073/pnas.0906606106, 2714280, 19625624.
20. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
21. Wang W, Guan KL. AMP-activated protein kinase and cancer. Acta Physiol (Oxf) 2009, 196:55-63.